FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3039744581> ?p ?o ?g. }

• W3039744581 endingPage "1804" @default.
• W3039744581 startingPage "1793" @default.
• W3039744581 abstract "Abstract The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study (NCT02181413) demonstrated improved progression-free survival with ixazomib maintenance versus placebo post autologous stem cell transplant (ASCT) in multiple myeloma patients. We report additional safety data from TOURMALINE-MM3 to inform adverse event (AE) management recommendations. Patients were randomized 3:2 to receive ixazomib ( n = 395) or placebo ( n = 261) on days 1, 8, and 15 of 28-day cycles for ~ 2 years or until progressive disease/toxicity. The initial 3-mg ixazomib dose was escalated to 4 mg in cycle 5, if tolerated in cycles 1–4. Safety was a secondary endpoint assessed in all treated patients; AEs were graded using Common Terminology Criteria for AEs v4.03. The rate of grade ≥ 3 AEs was higher in the ixazomib arm (19%) than in the placebo arm (5%), but the rate of discontinuation due to AEs was similar (7% vs. 5%). For AEs of clinical interest, rates were higher with ixazomib versus placebo: nausea 39% versus 15%, vomiting 27% versus 11%, diarrhea 35% versus 24%, thrombocytopenia 13% versus 3%, and peripheral neuropathy 19% versus 15%. However, the majority of events were low-grade, manageable with supportive therapy or dose reduction, and reversible, and did not result in discontinuation. There was no evidence of cumulative, long-term, or late-onset toxicity with ixazomib maintenance. Ixazomib is an efficacious and tolerable option for post-ASCT maintenance. AEs associated with ixazomib maintenance can be managed in the context of routine post-ASCT supportive care due to the limited additional toxicity. ClinicalTrials.gov NCT02181413" @default.
• W3039744581 created "2020-07-10" @default.
• W3039744581 creator A5002073335 @default.
• W3039744581 creator A5009590736 @default.
• W3039744581 creator A5010764419 @default.
• W3039744581 creator A5011827756 @default.
• W3039744581 creator A5012405296 @default.
• W3039744581 creator A5029159537 @default.
• W3039744581 creator A5033607303 @default.
• W3039744581 creator A5035289098 @default.
• W3039744581 creator A5056184409 @default.
• W3039744581 creator A5065131494 @default.
• W3039744581 creator A5068471072 @default.
• W3039744581 creator A5073477610 @default.
• W3039744581 creator A5078740906 @default.
• W3039744581 creator A5080776694 @default.
• W3039744581 creator A5082291347 @default.
• W3039744581 creator A5082774683 @default.
• W3039744581 creator A5090512266 @default.
• W3039744581 date "2020-07-01" @default.
• W3039744581 modified "2023-10-11" @default.
• W3039744581 title "Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma" @default.
• W3039744581 cites W1979068418 @default.
• W3039744581 cites W2035035521 @default.
• W3039744581 cites W2037132614 @default.
• W3039744581 cites W2097331346 @default.
• W3039744581 cites W2100545964 @default.
• W3039744581 cites W2114217833 @default.
• W3039744581 cites W2117237065 @default.
• W3039744581 cites W2125721471 @default.
• W3039744581 cites W2128084036 @default.
• W3039744581 cites W2143425592 @default.
• W3039744581 cites W2165065963 @default.
• W3039744581 cites W2167494200 @default.
• W3039744581 cites W2172122039 @default.
• W3039744581 cites W2343386476 @default.
• W3039744581 cites W2550414527 @default.
• W3039744581 cites W2599975475 @default.
• W3039744581 cites W2614011808 @default.
• W3039744581 cites W2737964630 @default.
• W3039744581 cites W2811293382 @default.
• W3039744581 cites W2887022567 @default.
• W3039744581 cites W2904294860 @default.
• W3039744581 cites W2904778784 @default.
• W3039744581 cites W2929187969 @default.
• W3039744581 doi "https://doi.org/10.1007/s00277-020-04149-5" @default.
• W3039744581 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7340660" @default.
• W3039744581 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32613281" @default.
• W3039744581 hasPublicationYear "2020" @default.
• W3039744581 type Work @default.
• W3039744581 sameAs 3039744581 @default.
• W3039744581 citedByCount "4" @default.
• W3039744581 countsByYear W30397445812021 @default.
• W3039744581 countsByYear W30397445812023 @default.
• W3039744581 crossrefType "journal-article" @default.
• W3039744581 hasAuthorship W3039744581A5002073335 @default.
• W3039744581 hasAuthorship W3039744581A5009590736 @default.
• W3039744581 hasAuthorship W3039744581A5010764419 @default.
• W3039744581 hasAuthorship W3039744581A5011827756 @default.
• W3039744581 hasAuthorship W3039744581A5012405296 @default.
• W3039744581 hasAuthorship W3039744581A5029159537 @default.
• W3039744581 hasAuthorship W3039744581A5033607303 @default.
• W3039744581 hasAuthorship W3039744581A5035289098 @default.
• W3039744581 hasAuthorship W3039744581A5056184409 @default.
• W3039744581 hasAuthorship W3039744581A5065131494 @default.
• W3039744581 hasAuthorship W3039744581A5068471072 @default.
• W3039744581 hasAuthorship W3039744581A5073477610 @default.
• W3039744581 hasAuthorship W3039744581A5078740906 @default.
• W3039744581 hasAuthorship W3039744581A5080776694 @default.
• W3039744581 hasAuthorship W3039744581A5082291347 @default.
• W3039744581 hasAuthorship W3039744581A5082774683 @default.
• W3039744581 hasAuthorship W3039744581A5090512266 @default.
• W3039744581 hasBestOaLocation W30397445811 @default.
• W3039744581 hasConcept C126322002 @default.
• W3039744581 hasConcept C141071460 @default.
• W3039744581 hasConcept C142724271 @default.
• W3039744581 hasConcept C197934379 @default.
• W3039744581 hasConcept C204787440 @default.
• W3039744581 hasConcept C27081682 @default.
• W3039744581 hasConcept C2776063141 @default.
• W3039744581 hasConcept C2776364478 @default.
• W3039744581 hasConcept C2776694085 @default.
• W3039744581 hasConcept C2777793932 @default.
• W3039744581 hasConcept C2778283404 @default.
• W3039744581 hasConcept C2778715236 @default.
• W3039744581 hasConcept C2780108899 @default.
• W3039744581 hasConcept C2781098529 @default.
• W3039744581 hasConcept C71924100 @default.
• W3039744581 hasConceptScore W3039744581C126322002 @default.
• W3039744581 hasConceptScore W3039744581C141071460 @default.
• W3039744581 hasConceptScore W3039744581C142724271 @default.
• W3039744581 hasConceptScore W3039744581C197934379 @default.
• W3039744581 hasConceptScore W3039744581C204787440 @default.
• W3039744581 hasConceptScore W3039744581C27081682 @default.
• W3039744581 hasConceptScore W3039744581C2776063141 @default.
• W3039744581 hasConceptScore W3039744581C2776364478 @default.
• W3039744581 hasConceptScore W3039744581C2776694085 @default.
• W3039744581 hasConceptScore W3039744581C2777793932 @default.

• next